1. Home
  2. UTSI vs SABS Comparison

UTSI vs SABS Comparison

Compare UTSI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTSI
  • SABS
  • Stock Information
  • Founded
  • UTSI 1991
  • SABS 2014
  • Country
  • UTSI China
  • SABS United States
  • Employees
  • UTSI N/A
  • SABS N/A
  • Industry
  • UTSI Telecommunications Equipment
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • UTSI Telecommunications
  • SABS Health Care
  • Exchange
  • UTSI Nasdaq
  • SABS Nasdaq
  • Market Cap
  • UTSI 25.4M
  • SABS 23.9M
  • IPO Year
  • UTSI 2000
  • SABS N/A
  • Fundamental
  • Price
  • UTSI $2.45
  • SABS $3.34
  • Analyst Decision
  • UTSI
  • SABS Strong Buy
  • Analyst Count
  • UTSI 0
  • SABS 5
  • Target Price
  • UTSI N/A
  • SABS $12.40
  • AVG Volume (30 Days)
  • UTSI 8.3K
  • SABS 83.3K
  • Earning Date
  • UTSI 09-05-2024
  • SABS 11-06-2024
  • Dividend Yield
  • UTSI N/A
  • SABS N/A
  • EPS Growth
  • UTSI N/A
  • SABS N/A
  • EPS
  • UTSI N/A
  • SABS N/A
  • Revenue
  • UTSI $14,958,000.00
  • SABS $1,512,723.00
  • Revenue This Year
  • UTSI N/A
  • SABS N/A
  • Revenue Next Year
  • UTSI N/A
  • SABS N/A
  • P/E Ratio
  • UTSI N/A
  • SABS N/A
  • Revenue Growth
  • UTSI 14.41
  • SABS N/A
  • 52 Week Low
  • UTSI $2.20
  • SABS $2.16
  • 52 Week High
  • UTSI $3.54
  • SABS $7.70
  • Technical
  • Relative Strength Index (RSI)
  • UTSI 36.82
  • SABS 48.06
  • Support Level
  • UTSI $2.57
  • SABS $2.75
  • Resistance Level
  • UTSI $2.80
  • SABS $4.30
  • Average True Range (ATR)
  • UTSI 0.15
  • SABS 0.51
  • MACD
  • UTSI -0.03
  • SABS 0.03
  • Stochastic Oscillator
  • UTSI 0.00
  • SABS 26.11

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp operates as a telecom infrastructure provider. It develops technology for bandwidth from cloud-based services, mobile, streaming, and other applications. The range of solutions is designed to expand and modernize telecommunications networks through smooth network system integration, lower operating costs, and increased broadband access. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. The company operates in China, India, Japan, Taiwan and other countries.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: